Brief Article
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 28, 2010; 16(32): 4066-4071
Published online Aug 28, 2010. doi: 10.3748/wjg.v16.i32.4066
Quality of life assessment in patients with chronic pancreatitis receiving antioxidant therapy
Nehal S Shah, Alistair J Makin, Aali J Sheen, Ajith K Siriwardena
Nehal S Shah, Aali J Sheen, Ajith K Siriwardena, Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom
Alistair J Makin, Department of Gastroenterology, Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom
Author contributions: Shah NS identified suitable recruits, interviewed the subjects, and collected and analyzed the data; Sheen AJ and Makin AJ were involved in identifying the subjects and editing the manuscript; Shah NS and Siriwardena AK designed the study; Siriwardena AK wrote the manuscript.
Supported by Central Manchester and Manchester Children’s Hospital Foundation Trust and by a Research Fellowship from Spire Healthcare Manchester (to Shah NS)
Correspondence to: Ajith K Siriwardena, Professor, Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, United Kingdom.
Telephone: +44-161-2764244 Fax: +44-161-2764530
Received: December 23, 2009
Revised: February 16, 2010
Accepted: February 23, 2010
Published online: August 28, 2010

AIM: To undertake a baseline study comparing quality of life (QoL) in patients with chronic pancreatitis (CP) on Antox to those with CP, matched for disease duration, who were not on this medication.

METHODS: CP was defined according to the Zurich classification. Sixty eight consecutive patients with CP who were taking Antox (antioxidants) were compared with 69 consecutive control CP patients not on Antox. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core questions 30 and Pancreatic Modification (28 questions) were used to assess QoL. Out of a total of 137 patients 28 in each group were matched for disease duration (within 12 mo). Median disease duration was 8 (1-22) years in the Antox group and 7 (1-23) years in the Non-Antox cohort (P = NS, Mann-Whitney U-test). Other parameters (age, gender, etiology, endocrine and exocrine insufficiency) were similar between groups.

RESULTS: Median visual analogue pain score in the Antox group was 3 (0-8) compared with 6 (0-8) in the Non-Antox group (P < 0.01). Perceptions of cognitive, emotional, social, physical and role function were impaired in the Non-Antox group compared to Antox patients (P < 0.0001, P = 0.0007, P = 0.0032 and P < 0.005 and P < 0.001, respectively). Analgesics and opiate usage was significantly lower in the Antox group (P < 0.01). Overall physical health and global QoL was better in the Antox group (P < 0.0001, 95% CI: 1.5-3).

CONCLUSION: Contemporary quality of life assessments show that after correction for disease duration and cigarette smoking, patients with CP taking antox had better scores than non-antox controls.

Keywords: Chronic pancreatitis, Antioxidants, Quality of life, Assessment, Management